RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
BioXcel Therapeutics Stock

BioXcel Therapeutics Net Income 2024

BioXcel Therapeutics Net Income

-96.49 M USD

Ticker

BTAI

ISIN

US09075P1057

WKN

A2JF20

In 2024, BioXcel Therapeutics's profit amounted to -96.49 M USD, a -46.11% increase from the -179.05 M USD profit recorded in the previous year.

The BioXcel Therapeutics Net Income history

YEARNET INCOME (undefined USD)
2029e85.05
2028e-9.8
2027e-41.67
2026e-52.58
2025e-73.78
2024e-96.49
2023-179.05
2022-165.76
2021-106.93
2020-82.17
2019-32.97
2018-19.27
2017-4.54
2016-2.12
2015-0.64

BioXcel Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into BioXcel Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by BioXcel Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects BioXcel Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of BioXcel Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into BioXcel Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing BioXcel Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on BioXcel Therapeutics’s growth potential.

BioXcel Therapeutics Revenue, EBIT and net profit per share

DateBioXcel Therapeutics RevenueBioXcel Therapeutics EBITBioXcel Therapeutics Net Income
2029e38.05 M undefined-28.87 M undefined85.05 M undefined
2028e98.02 M undefined-2.24 M undefined-9.8 M undefined
2027e58.85 M undefined-34.63 M undefined-41.67 M undefined
2026e21.73 M undefined-61.37 M undefined-52.58 M undefined
2025e6.84 M undefined-77.64 M undefined-73.78 M undefined
2024e4.05 M undefined-78.32 M undefined-96.49 M undefined
20231.38 M undefined-167.62 M undefined-179.05 M undefined
2022380,000 undefined-159.65 M undefined-165.76 M undefined
20210 undefined-106.94 M undefined-106.93 M undefined
20200 undefined-82.3 M undefined-82.17 M undefined
20190 undefined-33.6 M undefined-32.97 M undefined
20180 undefined-19.96 M undefined-19.27 M undefined
20170 undefined-4.54 M undefined-4.54 M undefined
20160 undefined-2.12 M undefined-2.12 M undefined
20150 undefined-640,000 undefined-640,000 undefined

BioXcel Therapeutics stock margins

The BioXcel Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of BioXcel Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for BioXcel Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the BioXcel Therapeutics's sales revenue. A higher gross margin percentage indicates that the BioXcel Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the BioXcel Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the BioXcel Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the BioXcel Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the BioXcel Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the BioXcel Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

BioXcel Therapeutics Margin History

BioXcel Therapeutics Gross marginBioXcel Therapeutics Profit marginBioXcel Therapeutics EBIT marginBioXcel Therapeutics Profit margin
2029e8.7 %-75.87 %223.55 %
2028e8.7 %-2.29 %-10 %
2027e8.7 %-58.84 %-70.8 %
2026e8.7 %-282.37 %-241.9 %
2025e8.7 %-1,135.52 %-1,079.08 %
2024e8.7 %-1,935.78 %-2,384.82 %
20238.7 %-12,146.3 %-12,974.86 %
202294.74 %-42,013.16 %-43,621.05 %
20218.7 %0 %0 %
20208.7 %0 %0 %
20198.7 %0 %0 %
20188.7 %0 %0 %
20178.7 %0 %0 %
20168.7 %0 %0 %
20158.7 %0 %0 %

BioXcel Therapeutics Aktienanalyse

What does BioXcel Therapeutics do?

BioXcel Therapeutics Inc. is a biotechnology company based in New Haven, CT, USA, focused on the development of novel therapeutics for severe neurological and psychiatric diseases as well as cancer. The company was founded in 2017 and is listed on the NASDAQ stock exchange. The founding of BioXcel Therapeutics Inc. was based on the concept that the combination of state-of-the-art data analytics technologies such as artificial intelligence (AI) and big data analysis with traditional biomedical approaches can open new opportunities in the field of drug discovery and development. The company utilizes its extensive database of clinical, genetic, molecular, and other data to identify targets and molecules that show promise for treating severe diseases. The business model of BioXcel Therapeutics Inc. includes both internal development and a licensing and partnership strategy. The company is working on various projects currently in different stages of clinical development. The key therapeutics currently in the company's pipeline include BXCL501, BXCL701, and BXCL702. BXCL501 is a novel treatment approach for acute anxiety and agitation in patients with schizophrenia, bipolar disorders, and Alzheimer's disease. The drug is based on a combination of DEX, an alpha-2 agonist, and melatonin. The company is currently planning a Phase III trial for BXCL501. BXCL701 is an oral immunoncology drug based on the inhibition of interleukin-12 and -23 and has the potential to treat various types of cancer. The drug is still in the clinical development phase. BXCL702 is a novel approach to treating pain in patients with peripheral neuropathic pain. The drug is currently in the preclinical development phase. BioXcel Therapeutics also operates a licensing and partnership strategy for drug development and commercialization. In November 2019, the company entered into an exclusive global licensing agreement with Nocion Therapeutics, a company specializing in the development of drugs for localized pain. Under this agreement, BioXcel Therapeutics will pursue the development and commercialization of Nocion's technology platform for the delivery of anesthetic drugs to patients with peripheral neuropathy. The company has also partnered with the Zambon Group, a leading European company in pharmaceutical and biotechnology research and development, and has entered into a research collaboration with Eisai Co. Ltd. BioXcel Therapeutics is an innovative company that combines the benefits of state-of-the-art data analytics technologies with traditional biomedical approaches to develop therapeutics for severe neurological and psychiatric diseases as well as cancer. The company has a well-stocked pipeline of promising drugs in various stages of clinical development and an effective licensing and partnership strategy that allows for further growth. BioXcel Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding BioXcel Therapeutics's Profit Margins

The profit margins of BioXcel Therapeutics represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of BioXcel Therapeutics's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating BioXcel Therapeutics's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

BioXcel Therapeutics's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When BioXcel Therapeutics’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about BioXcel Therapeutics stock

How much profit has BioXcel Therapeutics made this year?

BioXcel Therapeutics has made -96.49 M USD this year.

How has the profit developed compared to last year?

The profit has increased by -46.11% compared to last year fallen

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does BioXcel Therapeutics publish its earnings?

BioXcel Therapeutics publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of BioXcel Therapeutics?

The profits of BioXcel Therapeutics are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of BioXcel Therapeutics?

You can learn more about the earnings of BioXcel Therapeutics by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does BioXcel Therapeutics pay?

Over the past 12 months, BioXcel Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BioXcel Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of BioXcel Therapeutics?

The current dividend yield of BioXcel Therapeutics is .

When does BioXcel Therapeutics pay dividends?

BioXcel Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BioXcel Therapeutics?

BioXcel Therapeutics paid dividends every year for the past 0 years.

What is the dividend of BioXcel Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is BioXcel Therapeutics located?

BioXcel Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von BioXcel Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BioXcel Therapeutics from 12/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/19/2024.

When did BioXcel Therapeutics pay the last dividend?

The last dividend was paid out on 12/19/2024.

What was the dividend of BioXcel Therapeutics in the year 2023?

In the year 2023, BioXcel Therapeutics distributed 0 USD as dividends.

In which currency does BioXcel Therapeutics pay out the dividend?

The dividends of BioXcel Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The BioXcel Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von BioXcel Therapeutics

Our stock analysis for BioXcel Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BioXcel Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.